Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

chartwell rx, llc - letrozole (unii: 7lkk855w8i) (letrozole - unii:7lkk855w8i) - letrozole tablets, usp are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. letrozole tablets, usp are indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. the effectiveness of letrozole in extended adjuvant treatment of early breast cancer is based on an analysis of disease-free survival in patients treated with letrozole for a median of 60 months [ see clinical studies ( 14.2 , 14.3 ) ]. letrozole tablets, usp are indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer.letrozole tablets, usp are also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression fol

Իսրայել - անգլերեն - Ministry of Health

novartis israel ltd - letrozole - film coated tablets - letrozole 2.5 mg - letrozole - letrozole - femara (letrozole tablets) is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whome hormone receptor status cannot be determined locally advanced or metastatic breast cancer. femara is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - letrozole, quantity: 2.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; maize starch; sodium starch glycollate; iron oxide yellow; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 400 - treatment of postmenopausal women with hormone receptor positive breast cancer (see "clinical trials"). the safety and efficacy of neoadjuvant use has not been established. letrozole is not indicated in hormone receptor negative disease.

Կանադա - անգլերեն - Health Canada

teva canada limited - letrozole - tablet - 2.5mg - letrozole 2.5mg - antineoplastic agents

Կանադա - անգլերեն - Health Canada

meliapharm inc - letrozole - tablet - 2.5mg - letrozole 2.5mg - antineoplastic agents

Կանադա - անգլերեն - Health Canada

actavis pharma company - letrozole - tablet - 2.5mg - letrozole 2.5mg - antineoplastic agents

Կանադա - անգլերեն - Health Canada

taro pharmaceuticals inc - letrozole - tablet - 2.5mg - letrozole 2.5mg - antineoplastic agents

Կանադա - անգլերեն - Health Canada

fresenius kabi canada ltd - letrozole - tablet - 2.5mg - letrozole 2.5mg - antineoplastic agents

Կանադա - անգլերեն - Health Canada

pro doc limitee - letrozole - tablet - 2.5mg - letrozole 2.5mg - antineoplastic agents

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - letrozole, quantity: 2.5 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate; maize starch; magnesium stearate; lactose monohydrate; titanium dioxide; macrogol 8000; hypromellose; triacetin; iron oxide yellow; iron oxide red; quinoline yellow aluminium lake; polydextrose - for the treatment of postmenopausal women with hormone receptor positive breast cancer. the safety and efficacy of neoadjuvant use of letrozole has not been established. letrozole is not indicated in hormone receptor negative disease.